An ultra-sensitive and cost-effective diagnostic to improve AML patient outcome.
| Reference number | |
| Coordinator | Uppsala universitet - Institutionen för immunologi, genetik och patologi |
| Funding from Vinnova | SEK 2 200 000 |
| Project duration | July 2019 - June 2021 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
Purpose and goal
Taking advantage of the large amounts of DNA available from blood and bone marrow samples from AML patients, we have explored the possibility to apply the ultra-sensitive SafeLock assay for early detection of relapse of AML patients by detecting rare mutant sequences in a cost-effective manner. We aim to deploy the SafeLock assay in a clinical environment with minimal investment for instruments and staff training in order to operate assays for guiding therapy for individual patients.
Expected results and effects
We have successfully demonstrated that the SafeLock assay can reliably detect AML-related mutations from as little as 1 cell carrying the mutation among a total of 100,000 in both reference and patient samples. The analyses cab help the clinician adjust therapy for optimal effect and for early detection of relapse. We expect that the automated SafeLock assay will be implemented in clinical settings in the near future to improve AML patient care.
Planned approach and implementation
This Vinnova-funded project has been implemented effectively in cooperation between the Landegren and Cavelier research groups. Each party has concentrated on the allocated work packages in the application, designed to optimally exploit the competence of each party. The two parties have collaborated by sharing both staff as well as their respective research and clinical networks.